Kichang Han

Kichang Han

Auto-generated profile, based on publicly available information

Kichang Han

Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
KHKichang Han
Kichang Han
Jin Hyoung KimJin Hyoung Kim
Jin Hyoung Kim
Hepatocellular carcinoma (HCC), the fifth most common cancer that predominantly occurs in liver cirrhosis patients, requires staging systems to design treatments. The barcelona clinic liver cancer staging system (BCLC) is the most commonly used HCC management guideline. For BCLC stage B (intermediate HCC), transarterial chemoembolization (TACE) is the standard treatment. Many studies support the use of TACE in early and advanced HCC patients. For BCLC stage 0 (very early HCC), TACE could be an alternative for patients unsuitable for radiofrequency ablation (RFA) or hepatic resection. In patients with BCLC stage A, TACE plus RFA provides better local tumor control than RFA alone. TACE can serve as bridge therapy for patients awaiting liver transplantation. For patients with BCLC B, TACE provides survival benefits compared with supportive care options. However, because of the substantial heterogeneity in the patient population with this stage, a better patient stratification system is needed to select the best candidates for TACE. Sorafenib represents the first line treatment in patients with BCLC C stage HCC. Sorafenib plus TACE has shown a demonstrable effect in delaying tumor progression. Additionally, TACE plus radiotherapy has yielded better survival in patients with HCC and portal venous thrombosis. Considering these observations together, TACE clearly has a critical role in the treatment of HCC as a stand-alone or combination therapy in each stage of HCC. Diverse treatment modalities should be used for patients with HCC and a better patient stratification system should be developed to select the best candidates for TACE.

1 July 2015 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
KHKichang Han
Kichang Han
HKHeung Kyu Ko
Heung Kyu Ko
KKKyung Won Kim
Kyung Won Kim
HWHyung Jin Won
Hyung Jin Won
YSYong Moon Shin
Yong Moon Shin
PKPyo Nyun Kim
Pyo Nyun Kim

1 January 2021 in Radiology
Verified
Journal Article
Closed access
KHKichang Han
Kichang Han
Jin Hyoung KimJin Hyoung Kim
Jin Hyoung Kim
SYSeul Gi Yang
Seul Gi Yang
SPSeong Ho Park
Seong Ho Park
HCHyun-Kyung Choi
Hyun-Kyung Choi
MLMyeongjee Lee
Myeongjee Lee
Radiofrequency ablation provided long-term effectiveness in management of colorectal liver metastases, and a prediction model identified three independent risk factors for local tumor progression: ... Background Local tumor progression (LTP) is associated with poorer survival in patients undergoing radiofrequency ablation (RFA) for colorectal liver metastasis (CLM). An algorithmic strategy to pr...

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
KHKichang Han
Kichang Han
Jin Hyoung KimJin Hyoung Kim
Jin Hyoung Kim
GKGi-Young Ko
Gi-Young Ko
DGDong Il Gwon
Dong Il Gwon
KSKyu-Bo Sung
Kyu-Bo Sung
The natural history of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is dismal (approximately 2-4 mo), and PVTT is reportedly found in 10%-40% of HCC patients at diagnosis. According to the Barcelona Clinic Liver Cancer (BCLC) Staging System (which is the most widely adopted HCC management guideline), sorafenib is the standard of care for advanced HCC (i.e., BCLC stage C) and the presence of PVTT is included in this category. However, sorafenib treatment only marginally prolongs patient survival and, notably, its therapeutic efficacy is reduced in patients with PVTT. In this context, there have been diverse efforts to develop alternatives to current standard systemic chemotherapies or combination treatment options. To date, many studies on transarterial chemoembolization, 3-dimensional conformal radiotherapy, hepatic arterial chemotherapy, and transarterial radioembolization report better overall survival than sorafenib therapy alone, but their outcomes need to be verified in future prospective, randomized controlled studies in order to be incorporated into current treatment guidelines. Additionally, combination strategies have been applied to treat HCC patients with PVTT, with the hope that the possible synergistic actions among different treatment modalities would provide promising results. This narrative review describes the current status of the management options for HCC with PVTT, with a focus on overall survival.

1 March 2019 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
KHKichang Han
Kichang Han
KYKi Woong Yoon
Ki Woong Yoon
Jin Hyoung KimJin Hyoung Kim
Jin Hyoung Kim
GKGyoung Min Kim
Gyoung Min Kim

20 June 2018 in European Radiology
Verified
Journal Article
Closed access
PDF file
JKJoon Ho Kwon
Joon Ho Kwon
MKMan-Deuk Kim
Man-Deuk Kim
KHKichang Han
Kichang Han
WCWoosun Choi
Woosun Choi
YKYong Seek Kim
Yong Seek Kim
DLDo Yun Lee
Do Yun Lee